Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Feuilly M
Authors: Feuilly M, Cristeau O, Clay E, François C, Whalen J,
Keywords: somatostatin analogues, economics,
Introduction: CLARINET demonstrated the antitumour effect of LAN 120mg/28 days (standard interval) in metastatic gastroenteropancreatic NETs. If disease progresses (PD) on this dose, aggressive treatments (eg targeted therapies) are usually offered.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Pavel M, Dromain C, Majdi A, Houchard A,
Keywords: Lanreotide, dosing interval,
#1187 High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors
Introduction: Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Modica R
Authors: Modica R, Ramundo V, Marciello F, Marotta V, Pizza G,
Keywords: Somatostatin Analogs, Neuroendocrine Tumors,